NCT05137847View on ClinicalTrials.gov

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

CompletedOBSERVATIONAL

Enrollment

118

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions

Lymphoma, T-cell, PeripheralLymphoma, T-cell, Cutaneous

Interventions

DRUG

Remitoro

Intravenous infusion.

Trial Locations (3)

Unknown

Eisai Trial Site 3, Nagoya

Eisai Trial Site 1, Osaka

Eisai Trial Site 2, Tokyo

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY